Floatz logo

Mifepristone

Hypercortisolism

Corcept TherapeuticsSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hypercortisolism cohort.

Asset / SponsorPhaseRating
(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE
Corcept Therapeutics
Phase 3BBB
Clofutriben
Sparrow Pharmaceuticals
Phase 2CCC
Metyrapone
Istituto Auxologico Italiano
D
Semaglutide
University of Texas Southwestern Medical Center
N/AD
Solu-Cortef
University Hospital, Bordeaux
N/ANR

Same molecule, other indications

Mifepristone is also rated in:

psychotic disorderDormant
BB
Indicative ·
64 / 100
View asset →
major depressive disorderDormant
B
Indicative ·
63 / 100
View asset →
type 2 diabetes mellitusDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →